We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

136 hedge funds and large institutions have $1.16B invested in Nektar Therapeutics in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 51 increasing their positions, 47 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more capital invested

Capital invested by funds: $1.05B → $1.16B (+$111M)

9% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 47

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less call options, than puts

Call options by funds: $4.46M | Put options by funds: $4.61M

4% less funds holding

Funds holding: 142 → 136 (-6)

19% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 21

Holders
136
Holders Change
-6
Holders Change %
-4.23%
% of All Funds
3.95%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
51
Reduced
47
Closed
21
Calls
$4.46M
Puts
$4.61M
Net Calls
-$146K
Net Calls Change
-$7.96M

Top Buyers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
+$27.4M
2
First Trust Advisors
First Trust Advisors
Illinois
+$12.8M
3
State Street
State Street
Massachusetts
+$10.1M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$8.2M
5
GIM
Granahan Investment Management
Massachusetts
+$5.52M

Top Sellers

Rank Fund Capital Flow
1
MG
Meditor Group
Bermuda
-$15.1M
2
AG
Artal Group
Luxembourg
-$7.53M
3
PC
PointState Capital
New York
-$6.01M
4
ICM
IronBridge Capital Management
Illinois
-$5.92M
5
Barclays
Barclays
United Kingdom
-$5.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
76
ProShare Advisors
Maryland
$719K -$574K -3,562 -46%
US Bancorp
77
US Bancorp
Minnesota
$706K +$183K +1,132 +38%
SCA
78
SAC Capital Advisors
Connecticut
$666K +$631K +3,915 New
OAM
79
Oxford Asset Management
United Kingdom
$618K -$166K -1,030 -22%
Zurich Cantonal Bank
80
Zurich Cantonal Bank
Switzerland
$568K – – –
Connor, Clark & Lunn Investment Management (CC&L)
81
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$566K +$382K +2,367 +311%
Citadel Advisors
82
Citadel Advisors
Florida
$546K +$517K +3,206 New
Citigroup
83
Citigroup
New York
$544K +$172K +1,066 +50%
Creative Planning
84
Creative Planning
Kansas
$540K -$96.8K -600 -16%
Susquehanna International Group
85
Susquehanna International Group
Pennsylvania
$494K -$1.16M -7,196 -71%
PNC Financial Services Group
86
PNC Financial Services Group
Pennsylvania
$468K +$155K +960 +54%
TAM
87
Tocqueville Asset Management
New York
$454K +$53.9K +334 +14%
Public Employees Retirement Association of Colorado
88
Public Employees Retirement Association of Colorado
Colorado
$446K – – –
Bank of America
89
Bank of America
North Carolina
$372K +$12.9K +80 +4%
NSEDCP
90
NJ State Employees Deferred Compensation Plan
New Jersey
$341K – – –
DWA
91
Douglass Winthrop Advisors
New York
$340K – – –
RNS
92
Robert N. Shapiro
$329K – – –
LOM
93
Loeb Offshore Management
New York
$320K +$303K +1,877 New
Principal Financial Group
94
Principal Financial Group
Iowa
$289K -$59K -366 -18%
QBFM
95
QS Batterymarch Financial Management
New York
$273K +$258K +1,600 New
PCM
96
Prelude Capital Management
New York
$263K – – –
Barclays
97
Barclays
United Kingdom
$260K -$5.22M -32,384 -95%
SCM
98
Stevens Capital Management
Pennsylvania
$257K +$244K +1,512 New
KFS
99
KMS Financial Services
Washington
$227K +$215K +1,333 New
TD Asset Management
100
TD Asset Management
Ontario, Canada
$216K +$20.5K +127 +11%
2 3
4
5 6

NKTR Hedge Fund Activity: Q4 2013 in Review

136 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2013, worth a combined $1.16B — up 11% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of NKTR and 17 opened new positions — a net loss of 4 holders — while 47 trimmed existing stakes and 51 added.

The largest buyer was Primecap Management, adding an estimated $27.4M. The largest seller was Meditor Group, exiting entirely with an estimated $15.1M sold.

  • 136 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2013, down from 142 in Q3 2013.
  • Funds reported $1.16B of Nektar Therapeutics stock for Q4 2013, up 11% quarter-over-quarter.
  • 17 funds opened new Nektar Therapeutics positions in Q4 2013 and 21 closed out, a net change of -4 holders.
  • The largest Nektar Therapeutics buyer in Q4 2013 was Primecap Management, an estimated $27.4M added.
  • The largest Nektar Therapeutics seller in Q4 2013 was Meditor Group, an estimated $15.1M sold.

Based on aggregated 13F filings for Q4 2013.